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Abstract
The eradication of smallpox is one of the greatest medical successes in history. Vaccinia
virus was made famous by being the virus used in the live vaccine that enabled this feat.
Nearly 40 years on from that success, this prototypical poxvirus continues to empower the
exploration of fundamental biology and the potential to develop therapeutics against some
of the major causes of death and disease in the modern world.
In 1980, the World Health Organisation announced an extraordinary scientific achievement
that would change the course of human history: their 14-year international vaccination cam-
paign had finally and completely eradicated smallpox. This disease, caused by the poxvirus
variola, first appeared around 10,000 B.C. and was the most deadly human disease to ever
exist. With a devastating 20% to 60% mortality rate, smallpox killed an estimated 300 million
people in the 20th century alone and left its few survivors severely disfigured, with a third of
them blind [1].
The practice of vaccination had begun much earlier, in the 18th century. It was commonly
recognised at the time that milkmaids, who would catch cowpox from their cattle, never died
of smallpox. The English physician Edward Jenner then systematically infected individuals
with this nonlethal yet close relative of variola virus and showed that cowpox infection pro-
tected a person from smallpox. However, it took the World Health Organisation vaccination
campaign, now using a vaccine containing the poxvirus vaccinia, to finally rid the world of the
devastating killer [1,2].
Health officials subsequently stopped routine smallpox vaccinations because the risk of
using a live virus vaccine against a disease that no longer posed a threat far outweighed the
benefits. Due to its bioterrorism potential and likely lethality upon accidental exposure, scien-
tific research on variola virus is now restricted exclusively to government secure facilities
where the few remaining stocks of variola virus are kept safely under lock and key. Smallpox
has been defeated.
This extraordinary victory was achieved before I was born, so I never received a shot of vac-
cinia to protect me from smallpox. In fact, for most people alive today, vaccinia virus is simply the
vaccine once used to protect people from a disease that no longer exists. Despite this, just four
years ago, I established a research project to study the fundamental biology of vaccinia virus.
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I was excited to study vaccinia because, independent of its disease-eradicating heroism, this
virus is a powerful tool for cell biology research. Vaccinia virus lends itself to experimental
manipulation by being both relatively safe, and quick and easy to perform experiments with. It
can be handled at room temperature, maintains infectivity after multiple rounds of freeze-
thawing, and is able to infect a broad range of species and cell types. The virus naturally under-
goes homologous recombination during viral replication, which enables the easy addition or
deletion of genes from its genome, and its complete replication cycle only takes 8 to 12 hours.
Moreover, as it has been evolving alongside animals for thousands of years and is highly
adapted to control the host cell, establish its replicative niche inside the cell, and down-regulate
the host’s immune surveillance systems, I can learn a lot of cell biology by watching how it
does this.
In recent years, three specific vaccinia features have proved hugely valuable both for the
development of therapeutics to treat major public health threats as well as aiding the develop-
ment of cutting-edge imaging technologies that will be applicable to all areas of cell biology.
Firstly, vaccinia encodes almost all of its own replication machinery despite being an obli-
gate intracellular parasite. Many of these viral proteins are homologues of cellular proteins,
giving scientists like me a simpler system in which to begin to understand the function of the
closely related cellular proteins. For example, human cells encode over 600 kinase enzymes. As
a result, it is sometimes hard to define the role of an individual human kinase within the cell.
Vaccinia virus by contrast encodes just two kinases. One of these kinases, called B1, was first
identified in the 1980s. The kinase activity of B1 was extensively studied and shown to be
essential for viral DNA replication. A decade later, a screen for novel human proteins identi-
fied two proteins whose sequences were more than 40% identical to vaccinia B1, suggesting
that these proteins would also be active kinases [3]. Today, we know that there is a whole fam-
ily of human vaccinia-related kinases (VRKs) playing key roles in regulating cellular DNA rep-
lication, cell cycle progression, and cell proliferation. Given that cancers can establish
themselves when these processes go wrong, VRKs are implicated in several cancers including
liver, lung, and breast cancer [4–6]. As a result, this kinase family serves as potential targets for
developing cancer therapeutics, with comparative studies of vaccinia B1 still guiding under-
standing [4,7]
The second key vaccinia feature is its size. Boasting dimensions of 350 nm × 250 nm × 250
nm, vaccinia virus is large (for a virus!) and can be easily tracked by live cell microscopy. In
2008, the power of this feature was exemplified when a novel virus entry pathway into cells was
discovered using vaccinia [8]. Jason Mercer, a scientist in Zu¨rich, imaged vaccinia virions as
they interacted with the surface of human cells. Upon contact with the plasma membrane, the
virus caused the whole cell to produce blebs followed by the internalisation of the virion into a
large cellular intrusion. This process was highly reminiscent of the uptake of debris released
from dying cells, during a process called ‘apoptotic clearance’. Jason’s further experiments
showed that vaccinia displays lipids on its surface, making it look just like a piece of debris
shed from a dying cell, and thus vaccinia tricks cells into actively taking it up.
This ‘apoptotic mimicry’ entry pathway is now known to be employed by 20 clinically rele-
vant viruses, including chikungunya virus, dengue virus, hepatitis A virus, Lassa virus, Mar-
burg virus, and Ebola virus [9]. During the 2014–2016 outbreak, Ebola killed over 11,000
people [10]. Since then, the development of anti-Ebola therapeutics to combat future out-
breaks has garnered massive investment. Blocking the Ebola apoptotic mimicry entry pathway
is a promising approach. These life-saving studies are only possible because 10 years ago Jason
spent some time watching how a virus that does not even cause disease in humans, vaccinia,
gets into cells. This story illustrates the value of fundamental research aimed at better under-
standing biology rather than specifically developing therapeutics. Such studies consistently
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provide new understanding, which later enable the development of clinical therapies. No one
in 2008 would have predicted that Jason’s work with vaccinia would prove valuable in com-
batting Ebola epidemics. Yet performing the experiments with vaccinia was much safer and
quicker than performing them with Ebola.
The final key feature of vaccinia is its unusual subviral shape, which can clearly be seen by
electron microscopy (Fig 1). Poxviruses house their genome inside a peanut-shaped shell,
known as the virus core. Two additional protein structures, known as lateral bodies, sit on the
outer concave surface of this shell, and the whole lot is wrapped in a membrane. Although
unresolvable by standard light microscopy techniques, when fluorescently tagged, these three
subviral structures are resolvable using cutting-edge super-resolution microscopes. Large
amounts of stable vaccinia virions can easily be purified and bound directly to coverslips,
allowing the simultaneous imaging of hundreds of isolated virions. In these images, the elon-
gated core and flanking lateral bodies provide three-dimensional orientation information,
whereas the very small distance between the two lateral bodies challenges the resolution limit
of the microscope.
Two years ago, Rob Gray, a PhD student in London, combined all these features to develop
a piece of software that enhances the precision of the super-resolution images. His software
automatically detects individual viruses within the image, aligns them, and then averages them
together to produce high-confidence models with a 2-fold improvement in resolution. This is
a general software that can be applied to a wide array of other data sets independent of the
microscope used to collect the images [11].
Vaccinia has also proved to be a powerful tool to enhance the accuracy of super-resolution
microscopes. In her paper last year, Siaˆn Culley developed software to automatically detect
artifacts sometimes generated during the post-acquisition processing of super-resolution
microscopy images. Siaˆn used vaccinia images as test data sets during the development of the
software [12]. Their critical size and unusual subviral shape, combined with the plentiful elec-
tron microscope images available, made them ideal candidates for testing how well the soft-
ware was detecting problems in the super-resolution images.
Fig 1. An electron micrograph of vaccinia virus. The three subviral structures, core (C), lateral bodies (L), and
membrane (M), are labelled. Reproduced with permission of Jason Mercer.
https://doi.org/10.1371/journal.pbio.3000124.g001
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The super-resolution applications to date have employed isolated virions, but it seems likely
that soon, similar approaches will be applied to the context of the infected cells. Therefore, vac-
cinia is proving an excellent tool to aid the improvement of light microscopy approaches. It
follows that the better our microscopes, the more new biology we will be able to see and
understand.
The eradication of smallpox was undeniably a world-changing accomplishment, but vac-
cinia virus is more than simply the vaccine that enabled this feat. Vaccinia has a lot more biol-
ogy to teach us. With vaccinia virus as a tool, poxvirologists all over the world are pushing the
boundaries of technology, discovering fundamental biology, and developing therapeutics to
combat some of the major causes of death and disease in the modern world.
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